Aldeyra slides as lead drug flunks a primary endpoint in PhIIb
First things first.
Aldeyra’s Phase IIb study for its lead eye drug ADX-102 failed the primary endpoint in treating allergic conjunctivitis. And if you …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
